Literature DB >> 20950588

Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system.

Keisuke Yoshikawa1, Shiro Takei, Sanae Hasegawa-Ishii, Yoichi Chiba, Ayako Furukawa, Noriko Kawamura, Masanori Hosokawa, David F Woodward, Kikuko Watanabe, Atsuyoshi Shimada.   

Abstract

Prostaglandin (PG) F(₂α) is a product of cyclooxygenase (COX)-catalyzed metabolism of arachidonic acid and exerts biological functions in various tissues. Prostaglandin ethanolamide (prostamide) F(₂α) is a COX-2-catalyzed metabolite of arachidonoyl ethanolamide (anandamide) that induces pharmacological actions in ocular tissues. Although PGF(₂α) is one of the most abundant prostaglandins in the brain, function of PGF(₂α) in the central nervous system (CNS) has not been extensively investigated. Recently identified prostamide/PGF synthase catalyzes the reductions of prostamide H₂ to prostamide F(₂α) and PGH₂ to PGF(₂α), chiefly in the CNS. We examined tissue distribution of the enzyme in the CNS by immunohistochemistry, double immunofluorescence, and immuno-electron microscopy. We confirmed histological findings by immunofluorescence analyses of brain cell cultures. Prostamide/PGF synthase was expressed preferentially in the white matter bundles of the entire CNS of adult mice with less marked expression in neuronal cell bodies. The enzyme was colocalized with myelin basic protein (MBP) in myelin sheaths but not in axons. At the ultrastructural level, the enzyme was localized to myelin sheaths. Expression of the enzyme increased between P9 and P14 during the postnatal development, presumably in accordance with myelinogenesis. Cultured oligodendrocytes at 7 days in vitro expressed the enzyme in cytoplasmic processes where the enzyme was colocalized with MBP. Immunoreactivity for COX-2 was detected in white matter and cultured oligodendrocytes. Relatively selective localization of prostamide/PGF synthase suggests that myelin sheaths of the CNS may serve as the sites for producing prostamide F(₂α) and/or PGF(₂α), which may contribute to the formation and maintenance of central myelin.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950588     DOI: 10.1016/j.brainres.2010.10.019

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

Review 2.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

3.  Excitotoxicity-induced prostaglandin D2 production induces sustained microglial activation and delayed neuronal death.

Authors:  Kensuke Iwasa; Shinji Yamamoto; Sosuke Yagishita; Kei Maruyama; Keisuke Yoshikawa
Journal:  J Lipid Res       Date:  2017-02-07       Impact factor: 5.922

4.  Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability.

Authors:  Luisa Gatta; Fabiana Piscitelli; Catia Giordano; Serena Boccella; Aron Lichtman; Sabatino Maione; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

5.  4'-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation.

Authors:  Andrea Chicca; Maria Salomé Gachet; Vanessa Petrucci; Wolfgang Schuehly; Roch-Philippe Charles; Jürg Gertsch
Journal:  J Neuroinflammation       Date:  2015-05-13       Impact factor: 8.322

6.  Detection of genetic alterations in gastric cancer patients from Saudi Arabia using comparative genomic hybridization (CGH).

Authors:  Fehmida Bibi; Isse Ali; Muhammad Imran Naseer; Hussein Sheikh Ali Mohamoud; Muhammad Yasir; Sana Akhtar Alvi; Asif Ahmed Jiman-Fatani; Ali Sawan; Esam Ibraheem Azhar
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.